Healthcare Solutions Holdings Enters into a Definitive Agreement to Develop a Multispecialty Surgery Center and Multiple Advance Care Medical Complexes in the State of Arizona

2 years ago

GLEN COVE, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Healthcare Solutions Holdings Inc. (OTCPK: HSMD), a vertically-integrated health care system,…

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

2 years ago

SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the…

Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab

2 years ago

HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio…

German Federal Social Court Schedules Hearing on Classification of Exoskeleton Medical Devices for Spinal Cord Injured Individuals

2 years ago

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk"…

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

2 years ago

- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb -- BMS-986249 Phase 2 study ongoing - SOUTH SAN FRANCISCO,…

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

2 years ago

Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin…

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis

2 years ago

Topline data anticipated around year-end 2022NEW ORLEANS and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the…

AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022

2 years ago

Unique, intra-articular administration of AMB-05X yielded sustained, high synovial concentrations with low systemic exposures and positive clinical efficacyREDWOOD CITY, Calif.,…

SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer

2 years ago

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces…